Hormone Replacement Therapy Market Size Expected to Reach USD 21.49 Billion, exhibiting a CAGR of 6.1% by 2028
13 avr. 2023 02h38 HE
|
Fortune Business Insights
Pune, India, April 13, 2023 (GLOBE NEWSWIRE) -- The global hormone replacement therapy market size was USD 13.40 billion in 2020. The market is projected to grow from USD 14.17 billion in 2021 to...
Global Biopharmaceutical Market to Generate USD 974.48 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
02 août 2022 06h41 HE
|
Next Move Strategy Consulting
New York, Aug. 02, 2022 (GLOBE NEWSWIRE) -- According to the report published by Next Move Strategy Consulting, the global biopharmaceutical market generated USD 345.84 billion in 2021, and is...
Metabolomics Services Market Size ($1,895.14Mn by 2028) Led by Targeted Metabolomics Service (20.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
27 oct. 2021 14h11 HE
|
The Insight Partners
New York, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Metabolomics Services Market: Key InsightsAccording to our new research study on “Metabolomics Services Market Size and Forecast to 2028 - COVID-19 Impact...
Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
07 sept. 2017 07h50 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE...
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
03 août 2017 08h23 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced the pricing of its underwritten public...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
28 juil. 2017 07h30 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
27 juil. 2017 16h11 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics Reports First Quarter 2017 Financial Results
08 mai 2017 16h11 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three months ended March 31, 2017, and...
Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
27 avr. 2017 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...
ITL Pharma Receives United States Patent Protection for TriThroid® Using Sustained Drug Release and Improved Product Stability
14 févr. 2017 09h10 HE
|
ITL Pharma, Inc.
KINGSPORT, Tenn., Feb. 14, 2017 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Research Company, today announced awarding of a United States Patent (US 9,526,701) titled: "Sustained Drug Release...